Evolus is a performance beauty company specializing in injectable aesthetic products within the global cash-pay aesthetics market across the United States, Canada, Europe, and Australia. The company's flagship product, Jeuveau, is a proprietary botulinum toxin formulation designed to temporarily improve the appearance of moderate to severe frown lines in adults. Evolysse, its complementary portfolio offering, consists of injectable hyaluronic acid gels engineered with Cold-X Technology to address dynamic facial wrinkles. Evolus operates exclusively in the self-pay aesthetic segment, enabling a customer-centric business model distinct from competitors serving reimbursed markets. The company leverages a digital-first platform and consumer loyalty program to engage younger, wellness-conscious demographics. With approximately one million enrolled consumers in its Rewards program, Evolus positions itself at the intersection of medical aesthetics and consumer beauty, targeting the rapidly expanding segment of aesthetic neurotoxins and dermal fillers within the broader global aesthetics market.